Susquehanna International Group, LLP Allogene Therapeutics, Inc. Put Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$2.08 - $3.5 $8,944 - $15,050	4,300 Added 6.21%	73,500 $205,000
Q2 2024 Aug 15, 2024	BUY	$2.23 - $4.38 $85,855 - $168,630	38,500 Added 125.41%	69,200 $161,000
Q1 2024 May 07, 2024	BUY	$2.92 - $5.63 $52,852 - $101,903	18,100 Added 143.65%	30,700 $137,000
Q4 2023 Feb 14, 2024	BUY	$2.28 - $3.5 $28,727 - $44,100	12,600 New	12,600 $40,000
Q1 2023 May 16, 2023	BUY	$4.92 - $8.21 $171,216 - $285,708	34,800 Added 216.15%	50,900 $251,000
Q4 2022 Feb 14, 2023	BUY	$5.62 - $11.11 $22,480 - $44,440	4,000 Added 33.06%	16,100 $101,000
Q3 2022 Nov 14, 2022	BUY	$10.32 - $17.28 $17,544 - $29,376	1,700 Added 16.35%	12,100 $131,000

163

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $315M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.